1
PVX-001: open-source Covid-19 vaccine starts Phase 1 trial
First participants safely dosed in Melbourne, Australia, on August 31, 2026, in the first-in-human trial of our broadly-protective COVID-19 vaccine candidate PVX-001.
What it takes to design, test, manufacture, and deploy mRNA vaccines, personalized cancer medicines, and biosecurity therapeutics. Click to read The PopVax Chronicles, a Substack publication with hundreds of subscribers.
Visit chronicles.popvax.com → RSS feedOn Hacker News Oct 2026 – Oct 2026
First participants safely dosed in Melbourne, Australia, on August 31, 2026, in the first-in-human trial of our broadly-protective COVID-19 vaccine candidate PVX-001.